Literature DB >> 1586257

Bezafibrate induced rhabdomyolysis.

E Kanterewicz1, R Sanmartí, J Riba, I Trias, J Autonell, J Brugués.   

Abstract

The case is presented of a 70 year old woman with mild hypercholesterolaemia and hypertension who was readmitted to hospital six months after a previous admission for angina pectoris. The patient was treated with verapamil, nifedipine, and aspirin, and had been receiving bezafibrate (400 mg every 12 hours) for the previous 40 days. Twenty four hours after admission she developed podagra, which was treated with indomethacin (100 mg daily). Eight days after admission myocardial infarction was suspected, and the next day she presented with symptoms of rhabdomyolysis, which was confirmed by laboratory tests. Bezafibrate was withdrawn and the patient became asymptomatic after seven days. It is recommended that doctors should be aware of the possibility of patients, especially those with impaired renal function, developing rhabdomyolysis while being treated with bezafibrate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586257      PMCID: PMC1004709          DOI: 10.1136/ard.51.4.536

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  [Bezafibrate-induced necrotizing myopathy].

Authors:  C Gómez Manzano; J Fueyo; J Pedro-Botet Montoya; J Fernández-Solá
Journal:  Med Clin (Barc)       Date:  1991-03-23       Impact factor: 1.725

Review 2.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

3.  Lovastatin and rhabdomyolysis.

Authors:  J Z Ayanian; C S Fuchs; R M Stone
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

4.  Muscular syndrome after clofibrate.

Authors:  N Katsilambros; J Braaten; B D Ferguson; R F Bradley
Journal:  N Engl J Med       Date:  1972-05-18       Impact factor: 91.245

Review 5.  Clofibrate myopathy: a case report and a review of the literature.

Authors:  P Rush; M Baron; M Kapusta
Journal:  Semin Arthritis Rheum       Date:  1986-02       Impact factor: 5.532

Review 6.  Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.

Authors:  G F Blane
Journal:  Am J Med       Date:  1987-11-27       Impact factor: 4.965

7.  The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.

Authors:  A J Williams; F Baker; J Walls
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  [Acute severe myositis due to bezafibrate treatment].

Authors:  D Yeshurun; N Dakak; K Khoury; E Daher
Journal:  Harefuah       Date:  1989-03-01

10.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.

Authors:  C L Corpier; P H Jones; W N Suki; E D Lederer; M A Quinones; S W Schmidt; J B Young
Journal:  JAMA       Date:  1988-07-08       Impact factor: 56.272

View more
  3 in total

Review 1.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 2.  Fibrates in combination with statins in the management of dyslipidemia.

Authors:  Terry A Jacobson; Franklin H Zimmerman
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 3.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

Authors:  Jianyong Wu; Yan Song; Heng Li; Jianghua Chen
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.